Bortenat 3.5 (Bortezomib) 3.5 mg

Approved for the treatment of:

• Multiple Myeloma: Usually in combination with melphalan and prednisone (for untreated patients) or as monotherapy (for relapsed cases).
• Mantle Cell Lymphoma (MCL): In patients who have received at least one prior therapy.

⚠️ Professional Administration Only. DO NOT GIVE INTRATHECALLY.

Reconstitution for 3.5 mg Vial:

• For Intravenous (IV) use: Add 3.5 ml of 0.9% Sodium Chloride (Final conc. 1 mg/ml).
• For Subcutaneous (SC) use: Add 1.4 ml of 0.9% Sodium Chloride (Final conc. 2.5 mg/ml).

Administration: SC injection is often preferred to reduce the incidence of peripheral neuropathy. Rotate injection sites.

• Hypersensitivity to bortezomib, boron, or mannitol.
• Acute diffuse infiltrative pulmonary and pericardial disease.
• Pregnancy and breastfeeding (Potential hazard to the fetus).